Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Key facts
- Who runs it
- Antiva Biosciences
- Where
- Australia, Kenya, Mexico, and New Zealand24 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 141 people enrolled
- Started
- 27 Mar 2024
- Ended
- 20 Apr 2026
- Type of study
- Interventional, 11 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ABI-2280
- Record updated
- 17 August 2026
Who can take part
- Age
- 25 years to 55 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Female sex, 25 to 55 years of age
- Positive hrHPV result on at least 2 consecutive tests prior to randomization, one hrHPV+ result at least 12 months prior to screening
- Cervical cytology, colposcopy and/or biopsy performed within the last 6 months confirming disease status no greater than low-grade squamous intraepithelial lesions or cervical intraepithelial neoplasia grade 1
Who cannot take part
- History of biopsy or colposcopy indicating high-grade squamous intraepithelial lesions, or history of endocervical curettage positive for glandular dysplasia
- Any clinically significant immune suppressing condition
- History or current diagnosis of cervical cancer, suspected or confirmed
- Plan to have excision or ablation of cervical or vaginal lesions, or to undergo large loop excision of the transformation zone at any time during the study
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a blinded study to assess safety, tolerability, and efficacy of ABI-2280 vaginal inserts in participants diagnosed with persistent cervical hrHPV infection. This study will have up to 11 cohorts with various dose strengths and regimens. Each cohort will start with a sentinel cohort of 8 participants. Sentinel cohorts may be expanded to include an additional up to 32 participants to provide additional proof of concept data to further understanding of benefit/risk of a given dose/dose regimen.
The 11 groups in the trial
- Experimental: Cohort 1Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 1) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 2Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 2) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 3Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 3) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 4Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 4) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 5Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 5) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 6Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 6) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 7Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 7) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 8Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 8) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 9Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 9) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 10Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 10) or matching placebo
Treatment: ABI-2280
- Experimental: Cohort 11Existing treatment, for comparison
Participants in this arm will receive either ABI 2280 (Dose 11) or matching placebo
Treatment: ABI-2280
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts
- Record updated
- 17 August 2026